Refractory anemia with excess blasts type 1

Synonyms: RAEB-1

A severe type of RAEB characterized by cytopenias and the following hematological parameters: uni- or multilineage dysplasia 5% to 9% blasts in bone marrow or 2% to 4% in peripheral blood and no Auer rods (abnormal needle-shaped or round inclusions in the cytoplasm of myeloblasts and promyelocytes). Median survival has been reported to be 18 months.

Data from Orphanet are used to provide information on a disease's name, synonym(s), and overview. Reference: Access aggregated data from Orphanet at Orphadata. Orphadata: Free access data from Orphanet. © INSERM 1999. Available on http://www.orphadata.org. Data version April 2026

Newly diagnosed with
Refractory anemia with excess blasts type 1?

Our RARE Concierge Services Guides are available to assist you by providing information, resources and connections as you navigate your rare disease journey.

Get Concierge Help

Clinical Trials

For a list of clinical trials in this disease area, please click here.

Refractory anemia with excess blasts type 1

Get in touch with RARE Concierge.

Newly diagnosed with Refractory anemia with excess blasts type 1?

Related Content

Gilead To Discontinue Phase 3 Study of Magrolimab Plus Azacitidine in Higher-Risk MDS

FDA Expands Approval of Servier’s Therapy for Rare Form of Blood Cancers

The Lancet Publishes Geron’s Phase 3 Results in Lower Risk MDS

FDA Awards Keros Fast Track Designation for Experimental Therapy to Treat MDS

FDA Grants RMAT Designation to TScan’s Two Lead TCR-T Candidates for Blood Cancers

FDA Approves Geron’s Rytelo for Adults with Rare Blood Cancer

FDA Approves Gamida Cell’s Allogeneic Cell Therapy Omisirge for Hematological Malignancies

Clinical Trials

Newly diagnosed with
Refractory anemia with excess blasts type 1?